Editorial: Role of innate and adaptive immune cells in the metabolic syndrome.

Roy P, Winkels H, Orecchioni M, Quesada-Masachs E, Riffelmacher T
Frontiers in cell and developmental biology · 2024 · doi:10.3389/fcell.2024.1383642 · PMID:38455074 · PMC10917939
OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-26 ⓘ

This editorial discusses the role of innate and adaptive immune cells in metabolic syndrome, without providing specific findings or linking to endometriosis or adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-07 · read from full text ⓘ

This editorial examines the intricate interplay between innate and adaptive immune cells within the pathophysiology of metabolic syndrome. It highlights how chronic low-grade inflammation drives insulin resistance and other metabolic disturbances through complex cellular interactions. The authors synthesize current understanding of immune-mediated mechanisms contributing to systemic metabolic dysfunction without presenting new primary data. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,363 characters · extracted from epmc-fulltextxml · 4 sections · click to expand

Author

PR: Writing–original draft, Writing–review and editing. HW: Writing–review and editing. MO: Writing–review and editing. EQ-M: Writing–review and editing. TR: Writing–original draft, Writing–review and editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. HW is supported by Deutsche Forschungsgemeinschaft (GRK 2407: 360043781); SFB TRR259 (397484323 project A04 and A09 and project 535107899); the Center for Molecular Medicine Cologne; and the Neven-DuMont Foundation. MO is supported by American Heart Association’s Career Development Award (941152). EQ-M is supported by NIH R01AI092453.

Conflict

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher’S

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-09-20T09:27:46.357103+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC